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Intra-arterial and intravenous applications
of Iosimenol 340 injection, a new
non-ionic, dimeric, iso-osmolar
radiographic contrast medium: phase 2
experience
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Abstract
Background: Iosimenol 340 injection is a new, dimeric, iso-osmolar, iodinated contrast medium for X-ray angiography.
Purpose: To compare the safety and efficacy of iosimenol injection to iodixanol injection in two randomized, controlled
phase 2 trials.
Material and Methods: One hundred and forty-four adult patients were enrolled in the two trials, one for evaluation
during arteriography and the other for evaluation during computed tomography. Safety was compared by assessing
adverse events, vital signs, ECGs, and laboratory parameters. Efficacy was assessed as X-ray attenuation in the computed
tomography (CT) trial and as the quality of contrast enhancement in the arteriography trial.
Results: There were no statistically significant differences in terms of safety or efficacy between the two contrast media.
Both were well tolerated upon intravenous as well as intra-arterial injection. The most common adverse event was a
feeling of warmth (observed in 35.1% of the patients with Iosimenol injection and 44.3% with iodixanol injection).
Conclusion: Iosimenol upon intravenous as well as upon intra-arterial injection exhibits a safety profile and shows an
efficacy similar to that of iodixanol.
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Introduction
More than 80 million doses of iodinated contrast media
(CM) are administered annually (1). All approved
radiographic CM are derivatives of tri-iodo-benzoic
acid with X-ray attenuating properties proportional
to the iodine concentration of the final, formulated
product. Incremental improvements in safety and tol-
erance after vascular administration have been achieved
by reducing the number of moles of solute per kg water
in the final solution, thereby reducing the osmolality of
the contrast medium. The number of adverse drug reac-
tions was thus reduced by approximately 75% when
outcomes after injection of ionic, monomeric CM
are compared to that after injection of non-ionic,
monomeric CM (2). However, only dimerization
allows synthesis of CM which can be formulated as
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iso-osmolar to plasma (approximately 290 mOsm/kg)
while providing a sufficient concentration of iodine for
all clinical applications (3). The only commercially
available non-ionic, dimeric, iso-osmolar CM (iodix-
anol, VisipaqueTM), has been shown to reduce injection
associated discomfort (pain, heat) compared to non-
ionic, monomeric CM (4). It has been claimed that
the frequency of CM-induced nephropathy (CIN) is
lower (5), however this remains a controversial topic,
since other authors could not confirm that (6). Some
data even suggest improved in-hospital outcomes and a
reduction in major angiographic complications after
coronary angiography (7). A superior safety profile
was also reported in comparison to another dimeric
(but ionic) compound (ioxaglate, HexabrixTM) (8).
However, the low osmolality of iodixanol came at the
expense of increased viscosity, rendering injection
through very thin intra-arterial catheters harder (9).
In addition, the high viscosity per se may pose a renal
insult, as suggested by non-clinical data (10,11).
Iosimenol is a novel dimeric, non-ionic, iso-osmolar
CM with lower molecular weight and viscosity than
iodixanol at equal iodine concentration. Data from
the preclinical evaluation of iosimenol have been pro-
mising (12,13). The electro-physiologic cardiac
response in humans was excellent (i.e. minimal) (14)
and pharmacokinetic and initial safety data collected
during Phase 1 was similar to that of other contrast
media (15). In order to further evaluate the safety and
efficacy, two comparative clinical trials, one after intra-
venous injection (computed tomography [CT]) and one
after intra-arterial administration (digital subtraction
angiography [DSA]), were conducted.
Material and Methods
The safety, tolerance and efficacy of iosimenol injection
(provided by Koehler Chemie, Bensheim, Germany;
manufactured by Interpharma Praha a.s., Prague,
Czech Republic]) were compared to that of iodixanol
injection (VisipaqueTM, GE Healthcare, Chalfont St
Giles, Buckinghamshire, UK) in two randomized and
double-blind, bi-centric phase 2 trials conducted in
Germany, between May 2003 and July 2005. The
trials were approved by the local Ethics Committees
and conducted in accordance with Good Clinical
Practice, the German Drug Law and the 1964
Declaration of Helsinki with subsequent updates.
Written informed consent was obtained from all
patients. Only adult patients (18 years of age) were
enrolled. Patients with renal dysfunction (defined in the
intravenous trial as serum creatinine (SCr) >1.5mg/
100mL and in the intra-arterial trial as >2.0mg/
100mL) were excluded as were patients with severe
hepatic dysfunction or a history of any allergic
reactions to CM in both trials.
For the CT trial, 80 adult patients scheduled for CT
were enrolled and randomized to receive either iosime-
nol 340mg iodine/mL (42 patients) or iodixanol 320mg
iodine/mL (38 patients). A total of 100mL of CM was
applied by means of an automatic injector at a mean
rate of 2.3mL/s (0.31).
For the angiography trial, 64 adult patients sched-
uled for aortography and lower limb arteriography
were enrolled and randomly assigned to one of four
treatment groups (iosimenol 270mg iodine/mL; iosime-
nol 340mg iodine/mL; iodixanol 270mg iodine/mL; or
iodixanol 320mg iodine/mL). Patients were given as
many intra-arterial injections as considered necessary
for diagnostic purposes. Ranges of 15–60mL of CM
were administered for aortography and 30–35mL for
lower limb angiography, up to a total of 300mL.
Safety assessments
Safety was assessed by physical examination, electro-
cardiogram (ECG) recordings, vital signs (blood pres-
sure and pulse rate), and clinical laboratory parameters
for hematology and clinical chemistry. Safety evalu-
ations were performed at screening, baseline, and at
regular intervals until day 4 (72 h). A follow-up visit
was performed between days 6 and 8. Change in
serum creatinine (SCr) after injection of CM was used
as an indicator of CIN, defined as either a relative
increase in SCr of >25% or an absolute increase of
44.2mmol/L (6). Blood samples were collected at 24
and 72 h. The original ECGs were re-evaluated inde-
pendently after the end of the trial.
Adverse events (AEs) were assessed at each of the
time points for blood sampling and also by phone
after 6–8 days. Patients reporting possible AEs
during the phone call were further evaluated during
a subsequent follow-up visit. AEs occurring 2 h or
later after CM administration were classified as
having a late onset. The severity of AEs was evaluated
by the investigators as mild (did not interfere with
routine activities), moderate (interfered with routine
activities), or severe (prohibited routine activities).
The causality of AEs was classified as not related,
unlikely, possibly, probably, or highly probably
related. A simplified binary outcome of ‘‘not related’’
or ‘‘related’’ to the CM was used for the sake of this
publication, with not/unlikely related AEs included in
the first category and the remaining AEs accounted
for in the second. AEs were classified as serious
when causing death, being life-threatening, causing
hospitalization, significant, persistent, or permanent
disability or requiring medical interventions to prevent
permanent impairment.
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Efficacy assessments
In the CT trial X-ray attenuation (Hounsfield units) in
the aorta was measured 30–60 s after the start of the
injections. Measurements (TomoScan AV, Philips
Medical Systems Nederland B.V., Best, The
Netherlands and GE Hi Speed, GE Healthcare,
Chalfont St Giles, UK) were performed within regions
of interest (1.0–1.5 cm in diameter) in the aortic arch,
the descending thoracic, and/or suprarenal abdominal
aorta.
In the angiography trial three readers, blinded for
clinical and demographic data as well as trial drug,
independently assessed the image sets by region (abdo-
men, pelvis, thighs, lower legs, and ankles/feet as avail-
able). The quality of contrast enhancement (QCE) for
each region was assessed by a four-point rating scale.
Ratings of ‘‘excellent’’ and ‘‘good’’ were considered to
provide diagnostic quality contrast enhancement, while
ratings of ‘‘poor’’ or ‘‘none’’ were classified as provid-
ing non-diagnostic quality contrast enhancement. The
main efficacy endpoint was the overall QCE score for
each patient.
Each reader determined first whether the images
were technically adequate (evaluable) and only if they
were, continued the evaluation. Technically inadequate
was defined as improper positioning, artifacts and
patient movement which was the case in 2% of the
image sets.
Statistical analysis
Continuous safety variables were summarized with
descriptive statistics (N, mean, standard deviation,
median, minimum, and maximum), categorical vari-
ables by frequencies and percentages. 95% two-sided
exact confidence intervals were constructed according
to Clopper-Pearson. P values were calculated using
Fisher’s exact test. A P value of <0.05 was considered
statistically significant. All data processing and analyses
were performed with SAS Version 9.2 or higher (SAS
Institute, Heidelberg, Germany).
Results
Subjects
A total of 144 adult Caucasian patients (115 men, 29
women), with an age range of 22–84 years and body
mass index of 16–44 kg/m2 were enrolled in the two
trials (Table 1). Seventy-four patients received iosime-
nol (42 in the CT trial and 32 in the angiography trial)
and 70 iodixanol (38 in the CT trial and 32 in the angi-
ography trial). One randomized patient withdrew con-
sent and did not receive CM.
Safety
After injection of iosimenol, all 98 AEs observed were
of either mild or moderate intensity whereas six of 84
AEs in patients in the iodixanol group were severe.
Only one of them (headache) was, however, considered
as treatment related. AEs which occurred more than 2 h
after the injections were evenly distributed over 15
patients in each treatment group. They consisted
mainly of skin reactions, headache, and diarrhea.
Skin reactions were either mild or moderate in intensity
and mainly entailed erythema and pruritus (11 events
after the injection of iosimenol and 6 after the injection
of iodixanol). There were 71 treatment-related AEs
(adverse drug reactions [ADRs’]) in 41 (56.9%) patients
treated with iosimenol and 70 treatment-related AEs in
38 (54.3%) patients who received iodixanol (Table 2).
The frequency of AEs and ADRs was higher after
intra-arterial injections, where 23 patients (71.9%)
experienced ADRs after injection of iodixanol and 19
(59.3%) after injection of iosimenol. By far the most
commonly reported ADR after injection of both CM
was a feeling of warmth which was reported by 33.8%
of the patients after injection of iosimenol and 44.3%
after the injection of iodixanol. The frequency of
warmth was higher after intra-arterial injection,
43.7% and 59.4% for iosimenol and iodixanol, respect-
ively, compared to 26.2% and 31.6% after intravenous
injection. All other AEs occurred with a low frequency.
Table 1. Patient demographics (mean values and ranges).
Iosimenol (n¼ 74) Iodixanol (n¼ 70)
Men Women Total Men Women Total
Patients 55 19 74 60 10 70
Mean age (years) 58.5 (22–77) 62.5 (40–82) 59.5 (22–82) 62.4 (30–81) 65.6 (39–84) 62.8 (30–84)
Mean height (cm) 174.7 (162–196) 162.3 (152–170) 171.5 (152–196) 174.3 (160–192) 162.6 (152–170) 172.6 (152–192)
Mean weight (kg) 78.5 (59–125) 70.3 (47–100) 76.4 (47–125) 82.7 (53–143) 67.2 (43–96) 80.5 (43–143)
BMI (kg/m2) 25.8 (18–44) 26.6 (18–37) 26.0 (18–44) 27.1 (18–39) 25.5 (16–34) 26.8 (16–39)
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Headache was reported by eight patients, and nausea
and pruritus by five patients each. No injection-related
pain was reported.
Individual changes in vital signs were small and
within expected physiologic variability. None was con-
sidered as clinically significant.
No patient had an increase in heart rate exceeding 8
bpm and all recovered within a few minutes. Seven
patients had a change in QTcF in the range of 30–
60ms after injection of both CM. One patient had a
change >60 ms in the Iosimenol 270 group. There were
few ECG changes after contrast administration and all
occurred after intra-arterial injection, two in each
group. Overall there were no differences with regard
to effects on vital signs and ECG between the two CM.
Eight patients (10.8%) met the criteria for CIN after
injection of iosimenol and 12 (17.1%) after injection of
iodixanol (Table 3). Most of these patients (5 out of 8 in
the iosimenol group and 8 out of 12 in the iodixanol
group) had an eGFR >90mL/min at baseline; none of
them had an eGFR below 50mL/min before CM
administration (MDRD formula).
Efficacy
The aortic attenuation achieved in the CT trial was
slightly higher when iosimenol 340 was used compared
to iodixanol 320 (Table 4) One center systematically
reported higher attenuation values than the other par-
ticipating site. The average difference in aortic attenu-
ation between the two contrast media was 5% and 7%,
respectively, in favor of Iosimenol and was not statisti-
cally significant.
In the angiography trial the image sets from one
patient in the Iosimenol group were not retrievable
and consequently excluded from the evaluation.
Table 2. Summary of adverse events (AEs).
Intra-arterial injection
Group (n)
iosimenol
270 (16)
iodixanol
270 (16)
iosimenol
340 (16)
iodixanol
320 (16)
Total
iosimenol
(32)
Total
iodixanol
(32)
Patients with AE 10 (62.5%) 13 (81.3%) 11 (68.8%) 14 (87.5%) 21 (65.6%) 27 (84.3%)
Total number of AEs 26 24 20 29 46 53
Intensity (mild/moderate/severe) 22/4/0 22/2/0 18/2/0 21/3/5 40/6/0 43/5/5
Patients with related AEs (ADRs) 10 (62.5%) 12 (75.0%) 9 (56.2%) 11 (68.7%) 19 (59.3%) 23 (71.9%)
Related AEs (ADRs) 19 23 16 20 35 43
Intravenous injection
Group (n) iosimenol
340 (42)
iodixanol
320 (38)
Patients with AE (%) 20 (47.6%) 16 (42.1%)
Total number of AEs 52 31
Intensity (mild, moderate, severe) 34/18/0 25/5/1
Patients with related AEs (ADRs) 20 (47.6%) 15 (39.5%)
Related AEs (ADRs) 36 27
‘‘Related’’ comprises all AEs with relationship to drug use considered ‘‘highly probable’’, ‘‘probable’’, or ‘‘possible.
Table 3. Incidence of contrast-induced nephropathy.
CIN category
Iosimenol (n¼ 74) Iodixanol (n¼ 70)
n (%) [95% CI] n (%) [95% CI]
Total* 8 (10.8) [10.7, 29.7] 12 (17.1) [9.2, 28.0]
Serum creatinine increase >25% 8 (10.8) [10.7, 29.7] 12 (17.1) [9.2, 28.0]
Serum creatinine increase >44.2 mmol/L 0 (0.0) n.a. 1 (1.4) [0.0, 7.7]
*Differences between groups were not statistically significant.
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The complete image sets from one patient in the iosi-
menol and one in the iodixanol group were only eval-
uated by two of the three readers because of insufficient
contrast or artifacts. Both CM produced diagnostic
quality enhancement in at least 97% of the abdominal,
pelvis, and thigh images. Reader agreement was almost
100% with regard to the binary outcome of diagnostic
versus non-diagnostic quality of images, but lower
when all four rating categories were used. One of the
readers consistently tended to rate more images as
excellent (Table 5).
Discussion
Most AEs after the injection of iodinated CM are
known to be transient, self-limiting, and mild in inten-
sity (16). Typical manifestations include a sensation of
heat, nausea, occasional vomiting, skin rash, and hemo-
dynamic changes of minor clinical importance (2,4).
The frequency, type and severity of AEs in the present
trials were not different. Moreover, no significant dif-
ference between the iodixanol and iosimenol groups
was found. A feeling of warmth was by far the most
frequent AE occurring in the present study, encoun-
tered in 43.7% and 59.4% of the patients after intra-
arterial administration and 26.2% and 31.6% after
intravenous administration of iosimenol and iodixanol,
respectively. In a recent meta-analysis of 15 trials
(n¼ 5899) (4) more than 90% of the patients described
a sensation of heat after intra-arterial injection, irre-
spective of which CM was used. In this meta-analysis
the effects of iodixanol, the only iso-osmolar CM in the
analysis, compared favorably towards pooled compara-
tors with higher osmolality with regard to incidence
and severity of the sensation of heat.
Late onset of AEs is defined as an onset between 1 h
and 1 week after CM administration (17); most of these
AEs occur between 3 h and 2 days. (18). Therefore the
definition used in the present study (2 h to 1 week) is
considered adequate. Typically, the type of events does
not vary much with the time of occurrence. Late onset
AEs include nausea, vomiting, headache, itching, skin
rash, musculoskeletal pain, and fever (17,19,20). While
some authors report a higher incidence after injection
of iso-osmolar dimeric CM compared to injection of
monomeric CM with higher osmolality (21–23),
others claim that no such difference exists (24,25).
These seemingly divergent conclusions largely originate
from design issues of the trials the conclusions are
based on. The late AEs in our studies were in most
cases of mild intensity; about half of them were skin
reactions with a few more occurring in the iosimenol
group.
CIN, defined as a condition of decreased renal func-
tion within 3 days of intravascular administration of a
CM, in the absence of an alternative etiology, remains a
concern (6). While the course of CIN is usually benign
and transient, permanent renal failure requiring dialysis
is known to occur (26,27). Even more concerning is that
the frequency of patients in need of dialysis within a 2-
year period after exposure to an iodinated CM has been
reported as four times higher in patients with initial
laboratory findings of CIN compared to those without,
irrespective of whether the initial SCr increase returned
to normal in the immediate period after the event (28).
Bearing in mind that normal renal function as mea-
sured by SCr can be maintained in spite of significant
loss of functional nephrons, permanent damage can
Table 5. Overall image evaluation by reader/Arteriography trial.
Reader
Iosimenol Iodixanol
270 mgI/mL (n¼ 15*) 340 mgI/mL (n¼ 16) 270 mgI/mL (n¼ 16) 320 mgI/mL (n¼ 16)
Excellent Good Poor Excellent Good Poor Excellent Good Poor Excellent Good Poor
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
1y 1 (7) 13 (93) 0 (0) 8 (50) 7 (44) 1 (6) 3 (19) 13 (81) 0 (0) 0 (0) 14 (93) 1 (7)
2 3 (20) 12 (80) 0 (0) 7 (44) 9 (56) 0 (0) 3 (19) 13 (81) 0 (0) 4 (25) 12 (75) 0 (0)
3 11 (73) 4 (27) 0 (0) 14 (88) 2 (12) 0 (0) 14 (88) 2 (12) 0 (0) 15 (94) 1 (6) 0 (0)
*One patient’s images could not be retrieved.
yReader 1 did not evaluate one image set in the iosimenol 270, and one in the iodixanol 320 group due to insufficient contrast enhancement/artifacts.
Table 4. Contrast enhancement in Hounsfield Units/CT trial.
Treatment
Hounsfield Units (HU)
Mean Median
Site 1 Site 2 Site 1 Site 2
Iosimenol 340 185.34 263.21 176.0 256.4
Iodixanol 320 173.14 250.80 160.9 256.0
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occur also in patients who seemingly recover after an
episode of CIN. Such patients would be more vulner-
able to further renal insults from age, disease or
repeated CM injections, which would explain the
increased long-term renal morbidity.
In the two trials described here, CIN occurred in
eight out of 74 patients (10.8%) in the iosimenol
groups and in 12 out of 70 (17.1%) in the iodixanol
group with slightly more cases in the arteriography
trial which seems in line with historically reported
data. For instance, Morcos et al. reported an incidence
of 3.1–10.9% after intra-arterial administration and
2.6–8.5% after intravenous administration (27).
A potential drawback of higher viscosity in clinical
practice concerns injectability (9). Considering the
intravenous (CT) and intra-arterial (DSA) injections
through low-diameter lines with high flow rates, intra-
luminal pressure may become a safety issue. Catheters
with a larger diameter, on the other hand, may result in
more frequent vascular complications requiring post-
procedure transfusions and even causing major adverse
cardiac events (29).
In both trials the efficacy of iosimenol was compar-
able to that of iodixanol. The higher iodine concentra-
tion of iosimenol potentially contributed to a somewhat
higher rate of ‘‘excellent ‘‘images in the angiography
trial compared to iodixanol. This higher iodine content
probably also is the reason for the small difference in
contrast enhancement in the CT trial. The additionally
observed difference in contrast enhancement between
the two trial centers is most likely due to different scan-
ner types.
There are in particular three potential weaknesses of
the trials that should be mentioned. The low number of
patients enrolled does not allow for conclusions as to
subtle differences in the safety profile of the CM that
may yet be of clinical importance. Of particular interest
with regard to further exploration in larger trials, as
well as in high-risk populations, is the frequency of
CIN observed after injection of iosimenol when com-
pared to iodixanol. Second, the trials did not include
any comparison with the older, monomeric CM still
frequently used in clinical practice. Finally, the design
of the trials does not allow for any in depth comparison
of possibly clinically meaningful advantages attribut-
able to the diagnostic potential of the higher iodine
content of iosimenol.
In conclusion, iosimenol upon intravenous as well as
upon intra-arterial injection, exhibits a safety profile
and shows an efficacy similar to that of iodixanol.
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